# Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

> **NCT03170544** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 69 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** MK-1092, 4.0 nmol/kg
- **DRUG:** MK-1092, 8.0 nmol/kg
- **DRUG:** MK-1092, 16 nmol/kg
- **DRUG:** MK-1092, 32 nmol/kg
- **DRUG:** MK-1092, 64 nmol/kg
- **DRUG:** Glargine 3.0 nmol/kg
- **DRUG:** Lispro 1.2 nmol/kg
- **DRUG:** Placebo to glargine
- **DRUG:** Placebo to MK-1092
- **OTHER:** Dextrose
- **BIOLOGICAL:** Insulin

## Key facts

- **NCT ID:** NCT03170544
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2018-11-08
- **Final completion:** 2018-11-08
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03170544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03170544, "Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03170544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*